Abstract
Alzheimer's disease (AD) is the leading cause of dementia, characterized by neuropathological features such as amyloid-β (Aβ) plaques, neurofibrillary tau tangles, and neurodegeneration. Immunotherapy offers a promising potentially disease-modifying treatment for AD. We review recent advances in AD immunotherapy, specifically focusing on Aβ, tau, and neuroinflammation-targeted approaches, and gain insights from randomized controlled trials to propose disease-modifying directions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
